These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19916583)

  • 1. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.
    Gartlehner G; Thaler K; Hansen RA; Gaynes BN
    Drug Saf; 2009; 32(12):1159-73. PubMed ID: 19916583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.
    Gartlehner G; Thieda P; Hansen RA; Gaynes BN; Deveaugh-Geiss A; Krebs EE; Lohr KN
    Drug Saf; 2008; 31(10):851-65. PubMed ID: 18759509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.
    Gartlehner G; Gaynes BN; Hansen RA; Thieda P; DeVeaugh-Geiss A; Krebs EE; Moore CG; Morgan L; Lohr KN
    Ann Intern Med; 2008 Nov; 149(10):734-50. PubMed ID: 19017592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
    Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
    Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
    Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
    J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
    Hansen RA; Gartlehner G; Lohr KN; Gaynes BN; Carey TS
    Ann Intern Med; 2005 Sep; 143(6):415-26. PubMed ID: 16172440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation antidepressants for seasonal affective disorder.
    Thaler K; Delivuk M; Chapman A; Gaynes BN; Kaminski A; Gartlehner G
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008591. PubMed ID: 22161433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.
    Gartlehner G; Hansen RA; Morgan LC; Thaler K; Lux L; Van Noord M; Mager U; Thieda P; Gaynes BN; Wilkins T; Strobelberger M; Lloyd S; Reichenpfader U; Lohr KN
    Ann Intern Med; 2011 Dec; 155(11):772-85. PubMed ID: 22147715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
    Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
    Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.